Medtronic received FDA approval and is making available two Performa left ventricular quadripolar leads for use with Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-D). The leads now offer more options for placement thanks to the newly approved S and straight shaped devices in addition to the previously approved Dual Cant Model 4298 being available.
The leads have four electrodes that allow for sixteen different pacing configurations.
The three Attain Performa lead shapes -Dual Cant Model 4298, Straight Model 4398 and S-Shape Model 4598 -were designed to accommodate various anatomies without compromising lead handling or stability. With 16 pacing configurations and shorter spacing between the two center electrodes, these quadripolar leads have been shown to reduce the incidence of phrenic nerve stimulation (PNS), a potential issue associated with CRT therapy that results in muscle twitching, hiccups or shortness of breath.ii Attain Performa leads also include steroid elution on all four electrodes for lower chronic pacing thresholds, which contribute to greater device longevity and reduce the likelihood of PNS.
All three Attain Performa leads are compatible with the company’s newest portfolio of CRT devices, the Viva Quad XT and Viva Quad S CRT-D systems. The Viva Quad XT CRT-D features the Medtronic-exclusive AdaptivCRT® algorithm, which significantly improves heart failure patients’ response rate to therapy by preserving normal heart rhythms and automatically adapting to patient needs, creating a customized therapy for each patient. AdaptivCRT is the only algorithm demonstrated to improve heart failure patients’ response to the therapyiv (as compared to conventional biventricular therapy) and reduce the risk of atrial fibrillation, or AF.